Zoetis Inc. ZTS
71.05
0.78
1.11%
as of 25 Sep
- Market cap
- $29.2B
- P/E
- 11.7×
Follow ZTS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Zoetis Inc. (ZTS) P/S ratio
As of 25 September 2026, Zoetis Inc. (ZTS) trades at a P/S ratio of 3.1×. Over the past ten years it has ranged from 3.1× (September 2026) to 15.4× (December 2021); the current reading is higher than 0% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.3× and below the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 5.9× | (26.29%) |
| FY2024 | 8.0× | (24.65%) |
| FY2023 | 10.6× | 24.50% |
| FY2022 | 8.5× | (42.75%) |
| FY2021 | 14.9× | 26.27% |
| FY2020 | 11.8× | 16.63% |
| FY2019 | 10.1× | 42.50% |
| FY2018 | 7.1× | 7.07% |
| FY2017 | 6.6× | 21.91% |
| FY2016 | 5.4× | 8.15% |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 3.2× | (39.82%) |
| Mar 2026 | 5.2× | (11.17%) |
| Dec 2025 | 5.9× | (14.61%) |
| Sep 2025 | 6.9× | (6.76%) |
| 42 more quarters | Free account |
Against its own ten years
Low 3.1×
High 15.4×
Ten-year median
8.1×
Current reading's percentile
0
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| VTRS Viatris Inc. compare | 1.4× |
| TAK Takeda Pharmaceutical Co. compare | 2.0× |
| ELAN Elanco Animal Health Incorporated compare | 2.2× |
| HLN Haleon PLC Sponsored ADR compare | 2.4× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 2.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.8× |
| ZTS Zoetis Inc. | 3.1× |
| NBIX Neurocrine Biosciences, Inc. compare | 4.1× |
| UTHR United Therapeutics Corporation compare | 6.4× |
| Drug Manufacturers Specialty & Generic industry median | 2.3× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on ZTS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement